Clinical Trial Search

Primary: Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49 — 8.8; 10.2; 8.0; 8.0 Scores on a scale — p=0.759

Primary: Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response — 26.6; 16.7 percentage of participants — p=0.1448

Primary: Change in Adherence to Anithypertensives Based on Tablets Routine Questionnaire (TRQ) — 42.86; 21.24 percentage of days with missed doses — p=<0.001

Primary: Percentage of Participants From Each Stratum Who Demonstrated Correct Use of the ELLIPTA DPI at Visit 2, Attempt 1 (Day 28) — 92; 93 Percentage of participants

Primary: Change in Tablets Routine Questionnaire (TRQ, Past Week) From Screen to Week 25 Visit — 56.2 percentage of adherence — p=.012

Primary: Concentration of Triamcinolone Acetonide (TA) in Blood Plasma — 1061.8; 1104.1; 681.8; 3862.3 pg/mL

Primary: Change in HOMA-IR — 0; -1.5; -1.7 HOMA-IR score

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period — -49.17 Percent Change

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 9 Participants

Primary: PCSK-9 Level — 377.5; 322.53 ng/ml

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.3; 100.0; 84.2 percentage of participants

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time of Dose Extrapolated to Infinity (AUC[0-inf]) in Part 1 of DTG — 59.761; 101.125; 77.742 Hours*microgram…

Primary: Central Venous Pressure — 18.73; 14.91 mmHg

Primary: Change in Neurobehavioral Symptom Inventory — 35.2; 33.1; 27.7; 24.6 units on a scale

Primary: Progression Free Survival (PFS) — 6.47; 11.53 months — p=0.0005